Evidence map›Paper›PMID 11359904›Full record

ArticleMolecular and cellular biology2001

NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.

S Kreuz, D Siegmund, P Scheurich, H Wajant

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 235 papers.

0numbers the graph read from it
0cells of the map it votes in
235citing papers in PubMed
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

235 citing papers in PubMed, 575 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. PARP12-mediated mono-ADP-ribosylation as a checkpoint for necroptosis and apoptosis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. FLIPProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Recent advances in the role of gasotransmitters in necroptosis.Apoptosis : an international journal on programmed cell death · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

175 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S KreuzInstitute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany.
D Siegmund
P Scheurich
H Wajant
University of Stuttgart · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The caspase 8 homologue FLICE-inhibitory protein (cFLIP) is a potent negative regulator of death receptor-induced apoptosis. We found that cFLIP can be upregulated in some cell lines under critical involvement of the NF-kappaB pathway, but NF-kappaB activation was clearly not sufficient for cFLIP induction in all cell lines. Treatment of SV80 cells with the proteasome inhibitor N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG-132) or geldanamycin, a drug interfering with tumor necrosis factor (TNF)-induced NF-kappaB activation, inhibited TNF-induced upregulation of cFLIP. Overexpression of a nondegradable IkappaBalpha mutant (IkappaBalpha-SR) or lack of IkappaB kinase gamma expression completely prevented phorbol myristate acetate-induced upregulation of cFLIP mRNA in Jurkat cells. These data point to an important role for NF-kappaB in the regulation of the cFLIP gene. SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX). However, overexpression of IkappaBalpha-SR rendered SV80 cells sensitive to TRAIL-induced apoptosis in the absence of CHX, and cFLIP expression was able to reverse the proapoptotic effect of NF-kappaB inhibition. Western blot analysis further revealed that cFLIP, but not TRAF1, A20, and cIAP2, expression levels rapidly decrease upon CHX treatment. In conclusion, these data suggest a key role for cFLIP in the antiapoptotic response of NF-kappaB activation.

Indexed as

I-kappa B ProteinsIntracellular Signaling Peptides and ProteinsAntibodies, MonoclonalApoptosisBenzoquinonesCarrier ProteinsCASP8 and FADD-Like Apoptosis Regulating ProteinCD40 AntigensCell LineCycloheximideDNA-Binding ProteinsHeLa CellsHumansInterleukin-1Jurkat CellsLactams, MacrocyclicAntibodies, MonoclonalBenzoquinonesbenzyloxycarbonylleucyl-leucyl-leucine aldehydeCarrier ProteinsCASP8 and FADD-Like Apoptosis Regulating ProteinCD40 AntigensCFLAR protein, humanCycloheximideDNA-Binding ProteinsgeldanamycinI-kappa B ProteinsInterleukin-1Intracellular Signaling Peptides and ProteinsLactams, MacrocyclicLeupeptinsNF-kappa BNF-KappaB Inhibitor alphaNFKBIA protein, humanQuinonesReceptors, TNF-Related Apoptosis-Inducing LigandReceptors, Tumor Necrosis FactorTNFRSF10B protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID11359904
PMCPMC87059
OpenAlexW2135416318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.